Pancreatic Tumor - Pipeline Review, H2 2012 - This report 'Pancreatic Tumor - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Tumor. Pancreatic Tumor - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Pancreatic Tumor.
- A review of the Pancreatic Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pancreatic Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pancreatic Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pancreatic Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Pancreatic Tumor
Pancreatic Tumor Therapeutics under Development by Companies
Pancreatic Tumor Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Pancreatic Tumor Therapeutics – Products under Development by Companies
Pancreatic Tumor Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Pancreatic Tumor Therapeutics Development
Eli Lilly and Company
Novartis AG
Threshold Pharmaceuticals, Inc.
Pancreatic Tumor – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BEZ-235 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Temozolomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG 706 + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FOLFIRI - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Temodar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 + Sunitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Pertuzumab + Sandostatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Vinorelbine Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Octreotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Everolimus + Octreotide + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
X-82 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide + Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VCN-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BYL-719 + MEK-162 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Temozolomide + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH-302 + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatic Tumor Therapeutics – Drug Profile Updates
Pancreatic Tumor Therapeutics - Dormant Products
Pancreatic Tumor – Product Development Milestones
Featured News & Press Releases
Jun 19, 2012: Combination Of TH-302 And Radiation Reduces Human Pancreatic Tumor Growth In Hypoxic Xenografts, Study Finds
Nov 07, 2011: Pfizer Files Application For Additional Indication Of Sutent In Japan
Jul 22, 2011: Novartis Drug Afinitor Recommended By CHMP For EU Approval To Treat Patients With Advanced Pancreatic Neuroendocrine Tumors
Jun 15, 2011: VCN Biosciences Obtains Orphan Drug Designation From European Medicines Agency (EMA) To Their Candidate VCN-01 In The Treatment Of Human Exocrine Pancreatic Tumors
May 20, 2011: SUTENT Receives FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
May 05, 2011: Novartis's Afinitor Gains FDA Approval As First New Treatment For Patients With Advanced Pancreatic Neuroendocrine Tumors
Apr 12, 2011: FDA's Panel Recommends Approval of Novartis's Afinitor For Treatment Of Advanced Neuroendocrine Tumors
Apr 12, 2011: Pfizer's SUTENT Receives Favorable Review From FDA Panel
Jan 22, 2010: Pfizer Announces Phase III Trial Results Of Sutent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Pancreatic Tumor, H2 2012
Products under Development for Pancreatic Tumor – Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Eli Lilly and Company, H2 2012
Novartis AG, H2 2012
Threshold Pharmaceuticals, Inc., H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Pancreatic Tumor Therapeutics – Drug Profile Updates
Pancreatic Tumor Therapeutics – Dormant Products
List of Figures
Number of Products under Development for Pancreatic Tumor, H2 2012
Products under Development for Pancreatic Tumor – Comparative Analysis, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Pre-Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Combination Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012 26
